Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Stung By The US Again As Sales And Margins Fall In Q3

Sales Fall By 20% In US As Product Mix Impacts Core Operating Margin

Executive Summary

As parent Novartis announced plans for a strategic review for its Sandoz business, the generics and biosimilars unit posted falling sales again for the third quarter of 2021, after championing stability in Q2. Sandoz is banking on biosimilars to return to growth.

You may also be interested in...



Do Sandoz’ Q2 Results Indicate US Bottom Is In Sight?

Sandoz has been able to hike its previously flat full-year annual guidance following an upward trajectory for the company, especially in Europe and the US. One analyst pondered whether this suggested the “emergence of a bottom in the US generics sector” during the second half of the year.

Sandoz CEO Saynor Signals No Change To Focus Amid Strategic Review

Sandoz CEO Richard Saynor has told Generics Bulletin that the firm’s focus and strategy remain “unchanged” in the wake of last week’s announcement by parent company Novartis that it was exploring its options for the generics and biosimilars business.

Is Teva’s US Decline In Q3 Evidence Of A Broader Downward Trend?

Teva faced questions about the current environment in the US for generics, following weakness in its numbers and in those of rival Sandoz during the third quarter. Management remains “very committed to the US generics segment,” after sales dropped by 7%.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel